UnitedHealth Gears Up for Q3 Earnings: Should Investors Buy the Stock?

UNH heads into its October 13 Q3 2026 report with Wall Street expecting EPS of $4.12, a 41.1% jump year over year, even as revenue slips 1.6% to $111.38 billion.

That divergence is the setup. Earnings growth is projected to come from cost control rather than top-line expansion. Expectations rest on improved medical cost management and operational restructuring, which are supposed to drive margin expansion. Interpretation: the quarter hinges on whether UNH can hold medical costs down while shrinking.

The revenue drag is membership. UNH faces declining enrollment across commercial, Medicare Advantage, and Medicaid, so no major segment offers growth to offset losses. A beat on EPS paired with continued enrollment declines would show margin gains outrunning volume weakness.

Valuation offers a cushion. UNH trades at 17.15X forward earnings, below its historical valuation median. Interpretation: the multiple already reflects some skepticism, which could amplify upside if margin improvement shows up in the print.

HUM and MOH operate in overlapping segments, so UNH's cost and membership commentary may carry read-through for both names. That is an interpretation of segment overlap, not a reported catalyst.